NXP 900
Alternative Names: eCF-506; NXP-900Latest Information Update: 21 Aug 2025
At a glance
- Originator University of Edinburgh
- Developer Nuvectis Pharma; University of Edinburgh
- Class Antineoplastics; Carbamates; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Proto-oncogene protein c-yes inhibitors; Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Squamous cell cancer
Most Recent Events
- 11 Aug 2025 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Monotherapy) (PO)
- 31 Jul 2025 Pharmacodynamics, pharmacokinetics and adverse events data from a phase Ia trial in Solid tumours released by Nuvectis Pharma
- 08 Jul 2025 Adverse events and pharmacokinetics data from a drug-drug interaction trial released by Nuvectis Pharma